Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 4873 in Healthy Adult Human Subjects
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 4/21/2016 |
| Start Date: | April 2015 |
| End Date: | July 2015 |
A Phase 1, Multiple-Dose, Open-Label Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 4873 in Healthy Adult Human Subjects
This is a Phase 1, multiple dose, open-label pharmacokinetic study conducted in healthy
adult male and female subjects.
Subjects will receive 3 oral doses of WCK 4873 administered once-daily starting on Day 1.
Blood collection for determining plasma WCK 4873 concentrations will be conducted within 15
minutes prior to and at 1, 2, 3, 4, 6, 9, 12, and 24 hours after the first dose of WCK 4873.
The 24 hours post-dose sample after the first dose will be collected prior to Day 2 dosing.
Blood samples for determining plasma WCK 4873 concentrations will also be collected within
15 minutes prior to and at 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours after the third dose. Each
subject will undergo one standardized bronchoscopy with bronchoalveolar lavage (BAL) in the
outpatient bronchoscopy suite at 3, 6, 9, 12, 24 or 48 hours after the third oral dose of
WCK 4873. Subjects scheduled for bronchoscopy at 48 hours will also have blood sample drawn
for determining plasma WCK 4873 concentrations at 48 hours after the third dose.
Safety will be assessed throughout the study by adverse event monitoring, clinical
laboratory tests (including liver function tests), ECG, physical examination and vital sign
monitoring. Subjects will discontinue study drug administration in the event of AST/ALT
elevation of greater than 3 times the upper limit of normal.
adult male and female subjects.
Subjects will receive 3 oral doses of WCK 4873 administered once-daily starting on Day 1.
Blood collection for determining plasma WCK 4873 concentrations will be conducted within 15
minutes prior to and at 1, 2, 3, 4, 6, 9, 12, and 24 hours after the first dose of WCK 4873.
The 24 hours post-dose sample after the first dose will be collected prior to Day 2 dosing.
Blood samples for determining plasma WCK 4873 concentrations will also be collected within
15 minutes prior to and at 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours after the third dose. Each
subject will undergo one standardized bronchoscopy with bronchoalveolar lavage (BAL) in the
outpatient bronchoscopy suite at 3, 6, 9, 12, 24 or 48 hours after the third oral dose of
WCK 4873. Subjects scheduled for bronchoscopy at 48 hours will also have blood sample drawn
for determining plasma WCK 4873 concentrations at 48 hours after the third dose.
Safety will be assessed throughout the study by adverse event monitoring, clinical
laboratory tests (including liver function tests), ECG, physical examination and vital sign
monitoring. Subjects will discontinue study drug administration in the event of AST/ALT
elevation of greater than 3 times the upper limit of normal.
Inclusion Criteria:
- Body mass index (BMI) 18.5 and 30 (kg/m2) and weight between 55.0 and 100.0 kg (both
inclusive).
- Medical history without any major pathology as judged by the Principal Investigator.
- Resting supine blood pressure 100-139 (systolic) or 60-89 (diastolic) mm Hg, a
resting pulse rate of 40 beats per minute or higher, and showing no clinically
relevant deviations as judged by the Principal Investigator.
Exclusion Criteria:
- History or presence of significant oncologic, cardiovascular, pulmonary, hepatic,
renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic,
neurological, or psychiatric disease.
- Positive alcohol breath test or urine drug screen test at screening or confinement.
- Positive testing for HIV, Hepatitis B or Hepatitis C.
- Clinically significant pulmonary or any other disease that prevents a subject from
undergoing bronchoscopy with pulmonary lavage.
We found this trial at
1
site
Click here to add this to my saved trials
